- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI extends Mallinckrodt's FS069 rights
Molecular Biosystems of San Diego has extended Mallinckrodt Medical'srights to its FS069 ultrasound contrast agent to Europe, Russia,Africa, and India. In exchange for the new rights, Mallinckrodtof St. Louis will pay MBI fees of up to $12.9 million,
Molecular Biosystems of San Diego has extended Mallinckrodt Medical's
rights to its FS069 ultrasound contrast agent to Europe, Russia,
Africa, and India. In exchange for the new rights, Mallinckrodt
of St. Louis will pay MBI fees of up to $12.9 million, plus 40%
of product sales for royalties and manufacturing. The companies
filed a premarket approval application for U.S. marketing of FS069,
a second-generation contrast agent, earlier this year. They plan
to file for European approval in early 1997.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
